Acute Respiratory Distress Syndrome
Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome did not show a 60-day mortality benefit compared with conventional ventilation and ECMO rescue therapy. More adverse events occurred in the ECMO group with respect to bleeding requiring transfusion and severe thrombocytopenia.
In patients with very severe acute respiratory distress syndrome, 60-day mortality was not significantly lower with venovenous extracorporeal membrane oxygenation than with conventional treatment.
The risk for death in patients with community-acquired pneumonia who were given mechanical ventilation does not seem to be affected by the presence of acute respiratory distress syndrome.
After being treated for pyelonephritis and discharged to a nursing facility, a 67-year-old woman presents to the emergency department with shortness of breath.
In patients with acute respiratory distress syndrome, cisatracurium does not improve mortality when compared with vecuronium, but is associated with improvements in other outcomes.
Translational research has increased the understanding of the mechanisms of ventilator-induced lung injury.
A randomized trial sought to determine whether the use of titrated positive end-expiratory pressure influenced the 28-day mortality risk in patients with acute respiratory distress syndrome.
Treatments for acute respiratory distress syndrome that have less evidence to support their use have been overused by clinicians.
A low tidal volume ventilation strategy in patients with acute respiratory distress syndrome demonstrated a trend toward improved mortality.
Researchers examined the efficacy of conservative vs liberal fluid management in ARDS on disease mortality.
More than 300,000 individual ICU stays were examined to determine the benefit of ICU volume related to ARDS outcomes.
One year after hospital discharge, high rates of acute respiratory distress survivors are jobless.